Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals

被引:14
作者
Zhang, TianHong [1 ]
Wang, JunJie [2 ]
Xu, LiHua [1 ]
Wei, YanYan [1 ]
Tang, XiaoChen [1 ]
Hu, YeGang [1 ]
Cui, HuiRu [1 ]
Tang, YingYing [1 ]
Li, ChunBo [1 ]
Ling, Zheng [1 ]
Wang, JiJun [1 ,3 ,4 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai Key Lab Psychot Disorders, Sch Med, 13dz2260500, Shanghai 200030, Peoples R China
[2] Soochow Univ, Affiliated Guangji Hosp, Suzhou Guangji Hosp, Inst Mental Hlth, Suzhou 215137, Jiangsu, Peoples R China
[3] Shanghai Jiao Tong Univ, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai Mental Hlth Ctr, Sch Med,Bio X Inst,Minist Educ, 600 Wanping Nan Rd, Shanghai 200030, Peoples R China
[4] Shanghai Jiao Tong Univ, Brain Sci & Technol Res Ctr, Shanghai, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
Ultra-high risk; Transition; Poor function; Antipsychotic drugs; Outcome; CLINICAL HIGH-RISK; ULTRA-HIGH-RISK; CONSENSUS COGNITIVE BATTERY; INTERRATER RELIABILITY; 1ST-EPISODE PSYCHOSIS; PRODROMAL SYNDROMES; EPISODE PSYCHOSIS; DOSE EQUIVALENTS; FOLLOW-UP; SCHIZOPHRENIA;
D O I
10.1007/s00406-021-01331-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective Although existing guidelines have discouraged use of antipsychotics for general clinical high-risk (CHR) individuals, it is unclear if antipsychotics can prevent psychosis in higher-risk population. We aimed to study the comparative real-world effectiveness of antipsychotic treatments for preventing psychosis in higher-risk CHR individuals. Methods A total of 300 CHR individuals were identified using the structured interview for prodromal syndromes (SIPS) and followed the participants for 3 years. In total, 228(76.0%) individuals completed baseline assessments using the NAPLS-2 risk calculator (NAPLS-2-RC), and 210(92.1%) completed the follow-up. The sample was further stratified according to risk level. "Higher-risk" was defined based on the NAPLS-2-RC risk score (>= 20%) and SIPS positive symptom total scores (>= 10). The main outcome was conversion to psychosis and poor functional outcomes, defined as a global assessment of function (GAF) score lower than 60 at follow-up. Results In higher-risk CHR individuals, we found no significant difference in the rate of conversion to psychosis or poor functional outcomes between the antipsychotic and no-antipsychotic groups. Low-risk individuals treated with antipsychotic drugs were more likely exhibit poor functional outcomes compared with the no-antipsychotics group(NAPLS-2-RC estimated risk: chi(2) = 8.330, p = 0.004; Positive symptom severity: chi(2) = 12.997, p < 0.001). No significant effective factors were identified for prevention of the conversion to psychosis; conversely, CHR individuals who were treated with high dose antipsychotics (olanzapine, aripiprazole) showed a significantly increased risk of poor functional outcomes. Conclusions In CHR individuals, antipsychotic treatment should be provided with caution because of the risk of poor functional outcomes. Further, antipsychotic treatment does not appear to prevent onset of psychosis in real-world settings.
引用
收藏
页码:591 / 602
页数:12
相关论文
共 50 条
  • [1] Transition to Psychosis Associated With Prefrontal and Subcortical Dysfunction in Ultra High-Risk Individuals
    Allen, Paul
    Luigjes, Judy
    Howes, Oliver D.
    Egerton, Alice
    Hirao, Kazuyuki
    Valli, Isabel
    Kambeitz, Joseph
    Fusar-Poli, Paolo
    Broome, Matthew
    McGuire, Philip
    [J]. SCHIZOPHRENIA BULLETIN, 2012, 38 (06) : 1268 - 1276
  • [2] Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year follow-up
    Austin, Stephen F.
    Mors, Ole
    Secher, Rikke Gry
    Hjorthoj, Carsten R.
    Albert, Nikolai
    Bertelsen, Mette
    Jensen, Heidi
    Jeppesen, Pia
    Petersen, Lone
    Randers, Lasse
    Thorup, Anne
    Nordentoft, Merete
    [J]. SCHIZOPHRENIA RESEARCH, 2013, 150 (01) : 163 - 168
  • [3] Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review
    Beck, Katharina
    Andreou, Christina
    Studerus, Erich
    Heitz, Ulrike
    Ittig, Sarah
    Leanza, Letizia
    Riecher-Roessler, Anita
    [J]. SCHIZOPHRENIA RESEARCH, 2019, 210 : 39 - 47
  • [4] Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth
    Bobo, William V.
    Cooper, William O.
    Stein, C. Michael
    Olfson, Mark
    Graham, David
    Daugherty, James
    Fuchs, D. Catherine
    Ray, Wayne A.
    [J]. JAMA PSYCHIATRY, 2013, 70 (10) : 1067 - 1075
  • [5] Prediction of psychosis in youth at high clinical risk
    Cannon, Tyrone D.
    Cadenhead, Kristin
    Cornblatt, Barbara
    Woods, Scott W.
    Addington, Jean
    Walker, Elaine
    Seidman, Larry J.
    Perkins, Diana
    Tsuang, Ming
    McGlashan, Thomas
    Heinssen, Robert
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2008, 65 (01) : 28 - 37
  • [6] An Individualized Risk Calculator for Research in Prodromal Psychosis
    Cannon, Tyrone D.
    Yu, Changhong
    Addington, Jean
    Bearden, Carrie E.
    Cadenhead, Kristin S.
    Cornblatt, Barbara A.
    Heinssen, Robert
    Jeffries, Clark D.
    Mathalon, Daniel H.
    McGlashan, Thomas H.
    Perkins, Diana O.
    Seidman, Larry J.
    Tsuang, Ming T.
    Walker, Elaine F.
    Woods, Scott W.
    Kattan, Michael W.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2016, 173 (10) : 980 - 988
  • [7] A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program
    Carrion, Ricardo E.
    Correll, Christoph U.
    Auther, Andrea M.
    Cornblatt, Barbara A.
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 (01) : 64 - 74
  • [8] Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study
    Fusar-Poli, P.
    Frascarelli, M.
    Valmaggia, L.
    Byrne, M.
    Stahl, D.
    Rocchetti, M.
    Codjoe, L.
    Weinberg, L.
    Tognin, S.
    Xenaki, L.
    McGuire, P.
    [J]. PSYCHOLOGICAL MEDICINE, 2015, 45 (06) : 1327 - 1339
  • [9] Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies
    Fusar-Poli, P.
    Smieskova, R.
    Kempton, M. J.
    Ho, B. C.
    Andreasen, N. C.
    Borgwardt, S.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2013, 37 (08) : 1680 - 1691
  • [10] Can antidepressants prevent psychoses?
    Fusar-Poli, Paolo
    Valmaggia, Lucia
    McGuire, Philip
    [J]. LANCET, 2007, 370 (9601) : 1746 - 1748